Open an account

Gilead Sciences

GILD · NASDAQ

$156.51+$3.44 (+2.25%)TodayMarket closed ·
Prev close $153.07

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.

Employees
17,000
Headquarters
Foster City, California
Listed
Jan 22, 1992
Sector
Health Care
Industry
Biotechnology
Website
gilead.com

GILD key statistics

Market cap
189.80B
Price-earnings ratio
0.00
Dividend yield
3.17%
Average volume
5.63M
Volume
3.56M
Open price
$155.37
High today
$157.48
Low today
$154.02
52 Week high
$160.51
52 Week low
$114.02

Gilead Sciences (GILD) at a glance

As of Oct 20, 2026, Gilead Sciences (GILD) shares are priced at $156.51, giving the company a market cap of 189.80B, a price-to-earnings ratio of 0.00 and a dividend yield of 3.17%.

Today the stock has traded between $154.02 and $157.48. The current price is 1.6% above the day's low and 0.6% below its high.

Volume so far is 3.56M shares, below the average of 5.63M shares a day.

Over the past year Gilead Sciences has ranged from $114.02 to $160.51, and now sits 91% of the way up that range.

Gilead Sciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$6.75 per share against an estimate of -$7.38.

The average analyst price target is $161.70, 3.3% above the current price, from 18 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 18 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 31 analystsAvg $161.70
Low
$124.23
Now
$156.51
High
$189.00

GILD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 9.2% on average.

  1. Q3 FY24: reported $2.02 per share against an estimate of $1.59
  2. Q4 FY24: reported $1.90 per share against an estimate of $1.74
  3. Q1 FY25: reported $1.81 per share against an estimate of $1.82
  4. Q2 FY25: reported $2.01 per share against an estimate of $2.00
  5. Q3 FY25: reported $2.47 per share against an estimate of $2.17
  6. Q4 FY25: reported $1.86 per share against an estimate of $1.85
  7. Q1 FY26: reported $2.03 per share against an estimate of $1.95
  8. Q2 FY26: reported -$6.75 per share against an estimate of -$7.38

GILD news

  • Vandana Singh

    Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success

  • Press releaseBusiness Wire

    Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

  • Press releaseBusiness Wire

    Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

  • Vandana Singh

    Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

  • Snigdha Gairola

    Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Press releaseBusiness Wire

    Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

  • Press releasePRNewswire

    ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.

Similar companies

Companies in the same industry as Gilead Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.